AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
If you want AI, then you go with Medtronic." Coinbase: "Just go buy the Bitcoin, will you...We don't want the Coinbase, we want the Bitcoin." AbbVie: "AbbVie is just a gem...AbbVie is a winner ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics. The company's ratio of debt to EBITDA (earnings ...
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics.